Grants and Contributions:
Title:
COVID-19 Response: Rapid Prototyping and Deployment of a Fusogenix Vaccine and Immuno-therapeutic against COVID-19
Agreement Number:
949210
Agreement Value:
$100,000.00
Agreement Date:
May 1, 2020 - Dec 31, 2020
Description:
This project utilizes the Entos Fusogenix DNA delivery platform to rapidly develop, validate, manufacture and deploy countermeasures to protect the majority of the Canadian population from SARS-CoV-2 infection and COVID-19 disease.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T5J 4P6
Reference Number:
172-2020-2021-Q1-949210
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
816561112
Recipient Type:
For-profit organization
Recipient's Legal Name:
Entos Pharmaceuticals Inc.
Federal Riding Name:
Edmonton Centre
Federal Riding Number:
48014
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710